Please use this identifier to cite or link to this item:
|Title:||Chapter 11; Ensuring the Quality of Stem Cell-Derived In Vitro Models for Toxicity Testing|
|Authors:||STACEY Glyn; COECKE Sandra; PRICE Anna; HAUPT Simone; HEALY Lyn; INGELMAN-SUNDBERG Magnus; JAHNKE Heinz-Georg; JENNINGS Paul; KIDD Darren; LEMAITRE Gilles; LOUISSE Jochem; PINSET Christian; ROBITSKI Andrea; WILMES Anja; MYATT Glenn|
|Type:||Articles in periodicals and books|
|Abstract:||Quality control of cell cultures used in new in vitro toxicology assays is crucial to the provision of reliable, reproducible and accurate toxicity data on new drugs or constituents of new consumer products. This chapter explores the key scientific and ethical criteria that must be addressed at the earliest stages of developing toxicology assays based on human pluripotent stem cell (hPSC) lines. It also identifies key considerations for such assays to be acceptable for regulatory, laboratory safety and commercial purposes. Also addressed is the development of hPSC-based assays for the tissue and cell types of greatest interest in drug toxicology. The chapter draws on a range of expert opinion within the European Commission/Cosmetics Europe-funded alternative testing cluster SEURAT-1 and consensus from international groups delivering this guidance such as the International Stem Cell Banking Initiative. Accordingly, the chapter summarizes the most up-date best practices in the use and quality control of human Pluripotent Stem Cell lines in the development of in vitro toxicity assays from leading experts in the field.|
|JRC Directorate:||Health, Consumers and Reference Materials|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.